Online Course
on demand
28
Sep
2026
28
Sep
2026
Tumour sites
Precision oncology in breast cancer: from diagnostics to biomarker-driven treatment strategies
Background
The course will bring together an international faculty of experts to discuss the latest advances in precision oncology for HER2-positive breast cancer, from diagnostic imaging and biomarker identification to personalised treatment strategies and future clinical implementation. Through evidence-based presentations and interactive discussions, participants will gain practical insights into translating emerging evidence into multidisciplinary clinical practice.
 
Learning Objectives
- To review current and emerging diagnostic approaches in HER2-positive breast cancer.
- To discuss the role of biomarkers in patient selection and treatment planning.
- To explore personalised treatment strategies, including escalation and de-escalation approaches.
- To examine the clinical implementation of biomarker-driven precision oncology.

Main Topics
- Precision diagnostics in breast cancer
- Diagnostic biomarkers and patient selection
- Personalised treatment strategies in HER2-positive breast cancer
- Escalation and de-escalation strategies
- HER2DX and biomarker-driven clinical decision-making
- Future perspectives in precision oncology

Accreditation and Certificates
Application for CME accreditation has been submitted to the Accreditation Council of Oncology in Europe (ACOE).
The programme was recognised as being of high quality from both a scientific and didactic point of view and was awarded 3 CME credits.
Participants will be issued a certificate of attendance (minimum attendance: 75% of the entire course). An online evaluation questionnaire and learning assessment test will need to be completed in order to get the certificate that will be issued by email.
 
Acknowledgements
Funded by the European Union – Horizon Europe Grant Agreement No. 101136953.
Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or HADEA. Neither the European Union nor the granting authority can be held responsible for them.
This work has also received funding from the Swiss State Secretariat for Education, Research and Innovation (SERI).

28/09/2026 12:00 CEST

Agenda

28/09/2026 12:00 CEST

Welcome and introduction

Chair: Matti Aapro, CH
Chair: Seamus O’Reilly, IE
28/09/2026 12:05 CEST

Precision diagnostics in breast cancer

•  From imaging to molecular characterisation
•  Current and emerging diagnostic biomarkers
•  Challenges in patient selection for precision oncology
•  Discussion and Q&A
Chair: Matti Aapro, CH
Chair: Seamus O’Reilly, IE
Expert: Paola Clauser, AT
Expert: Esther Sanfeliu, ES
28/09/2026 13:00 CEST

Personalising treatment strategies in HER2-positive breast cancer

•  Optimising treatment pathways in early disease
•  Escalation and de-escalation strategies 
•  Translating evidence into multidisciplinary decision-making
•  Discussion and Q&A
 
Chair: Matti Aapro, CH
Chair: Seamus O’Reilly, IE
Expert: Monika Gräser, DE
Expert: Gaia Griguolo, IT
28/09/2026 13:55 CEST

Biomarker-driven care: from HER2DX to future clinical implementation

•  HER2DX in clinical practice
•  Biomarkers and clinical trial development
•  Future directions in precision oncology
•  Discussion and Q&A
 
Chair: Matti Aapro, CH
Chair: Seamus O’Reilly, IE
Expert: Marta González, ES
Expert: Francesco Schettini, ES
28/09/2026 14:50 CEST

Closing remarks

Chair: Matti Aapro, CH
Chair: Seamus O’Reilly, IE
Matti Aapro
Sharing Progress in Cancer Care and Clinique de Genolier, Bellinzona and Genolier, Switzerland
Paola Clauser
Medical University of Vienna, Vienna, Austria
Marta González
Medical oncologist, Breast Cancer Research Program Fundació Clínic per a la Recerca Biomèdica (FCRB) at Hospital Clínic de Barcelona, Barcelona, Spain
Monika Gräser
Senior Consultant and Head Physician of the Breast Cancer Center Witten at Marien Hospital Witten, Witten, Germany
Gaia Griguolo
Department of Surgery, Oncology and Gastroenterology at University of Padua, Padua, Italy
Seamus O’Reilly
Consultant Medical Oncologist at Cork-Mercy and South Infirmary Victoria University Hospitals, Cork, Ireland
Esther Sanfeliu
Biomedical Diagnostic Centre (CDB), Hospital Clínic de Barcelona, Barcelona, Spain
Francesco Schettini
Medical Oncology Department at Hospital Clinic of Barcelona, Translational Genomics and Targeted Therapies in Solid Tumors Group, FRCB-IDIBAPS, Barcelona, Spain
This material is part of Educational Project:
2023-2028 DEFINITIVE project